STOCK TITAN

NuCana plc American Depositary Share - NCNA STOCK NEWS

Welcome to our dedicated page for NuCana plc American Depositary Share news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on NuCana plc American Depositary Share stock.

NuCana plc (NASDAQ: NCNA) is a pioneering clinical-stage biopharmaceutical company dedicated to enhancing treatment outcomes for cancer patients. The company leverages its innovative ProTide technology to transform widely used chemotherapy drugs into more potent and less toxic medications. NuCana's core focus is on overcoming resistance mechanisms in cancer cells, thus achieving higher concentrations of anti-cancer metabolites within the tumors.

NuCana’s cutting-edge research and development pipeline include key products such as NUC-3373, NUC-7738, and Acelarin. These are aimed at treating various solid tumors which are often challenging to manage with conventional therapies due to drug resistance and severe side effects.

The firm is committed to advancing its clinical programs aggressively. NUC-3373 is being evaluated in several ongoing studies, including a Phase 2 trial for advanced colorectal cancer, where it's shown promising efficacy and safety. Similarly, NUC-7738 is under investigation for its potential in treating melanoma and other solid tumors, especially in patients who have not responded to previous treatments.

In recent updates, NuCana announced their financial results for the third and fourth quarters of 2023. As of December 31, 2023, NuCana had £17.2 million in cash and cash equivalents. The company reported a net loss of £7.7 million for Q4 2023, a significant improvement compared to the £15.2 million loss in Q4 2022. The ongoing clinical trials and promising data presentations for their ProTide products demonstrate the potential for improved cancer treatments.

Additionally, NuCana’s recent changes in the ADS ratio, effective as a one-for-twenty-five reverse split, aim to enhance the liquidity of their ADSs and regain compliance with Nasdaq's minimum bid price requirement. The company's shares continue to trade under the ticker symbol “NCNA”.

Through strategic partnerships and robust clinical development, NuCana plc is poised to make significant strides in oncology therapeutics, contributing to better patient outcomes and advancing the future of cancer treatment.

Rhea-AI Summary

NuCana reported Q3 2024 financial results and clinical updates. The company presented promising Phase 2 data for NUC-7738 in combination with pembrolizumab, showing disease control in 9 of 12 PD-1 inhibitor-resistant melanoma patients. Phase 1b/2 data for NUC-3373 showed encouraging results in combination with pembrolizumab or docetaxel. Financial highlights include cash position of £11.4 million as of September 30, 2024, with runway expected into Q2 2025. The company reported a reduced net loss of £4.5 million compared to £6.7 million in Q3 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary

NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target lesion reduction and a melanoma patient showing 81% reduction. In Module 2, NUC-3373 with docetaxel demonstrated extended stable disease in lung cancer patients, with one achieving stability for over 13 months. The combinations were generally well-tolerated, though Module 2 enrollment was paused due to docetaxel-related toxicity concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
-
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) has announced the issuance of a new composition-of-matter patent for NUC-7738 by the United States Patent and Trademark Office (USPTO). This patent (US12,054,510) is a important addition to NUC-7738's intellectual property protection, which now includes over 80 issued patents worldwide.

NUC-7738, a novel anti-cancer agent, is currently in a Phase 2 clinical study combined with pembrolizumab for PD-1 inhibitor resistant melanoma patients. Recent data presented at the ESMO Congress 2024 showed encouraging results, with the majority of patients achieving a progression-free survival of more than 5 months, compared to the current standard of care of 2-3 months.

Hugh S. Griffith, NuCana's CEO, emphasized the importance of this patent in strengthening NUC-7738's intellectual property protection and highlighted its potential to make previously resistant tumors sensitive to PD-1 inhibitor rechallenge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.84%
Tags
none
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress 2024, showcasing encouraging results for NUC-7738 in combination with pembrolizumab for metastatic melanoma patients refractory to or relapsed on prior PD-1 inhibitor therapy. The study, involving 12 patients, demonstrated a 75% disease control rate, including two partial responses. Notably, 7 out of 12 patients achieved progression-free survival exceeding five months, which is significant for this patient population. The combination therapy also exhibited a favorable safety profile. NUC-7738's mechanism of action, targeting multiple aspects of the tumor microenvironment, is believed to sensitize PD-1 resistant tumors to rechallenge with PD-1 inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) announced the discontinuation of its NuTide:323 study following a pre-planned analysis and recommendation from the Steering Committee. The study, which aimed to develop NUC-3373 as a replacement for 5-FU in second-line colorectal cancer treatment, was unlikely to achieve its primary objective of superior Progression Free Survival compared to the control arm.

Despite this setback, NuCana remains committed to its ongoing development programs. The company will continue with the NuTide:701 and NuTide:303 studies, focusing on NUC-7738 in combination with pembrolizumab. Encouraging data from these studies will be presented at the ESMO Annual Conference in September 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.4%
Tags
-
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) reported Q2 2024 financial results and provided a business update. Key points include:

- Cash and cash equivalents of £11.6 million as of June 30, 2024
- Net loss of £7.0 million for Q2 2024
- Loss per ordinary share of £0.12

The company is advancing clinical programs for NUC-3373 (ProTide transformation of 5-FU) and NUC-7738 (ProTide transformation of 3'-deoxyadenosine). Multiple data readouts are expected in H2 2024, including updates from Phase 2 studies in colorectal cancer and melanoma. NuCana anticipates its cash runway to extend into Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 PM EDT in New York, NY. The presentation will be webcast live and made available for replay in the Investors section of the NuCana website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
-
Rhea-AI Summary

NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at TD Cowen’s 5th Annual Oncology Innovation Summit on May 28, 2024, at 8:30 AM EDT. This virtual event will offer insights related to ASCO & EHA. The live webcast and replay will be accessible through the Investors section of NuCana's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
Rhea-AI Summary

NuCana (NASDAQ: NCNA) has released its financial results for Q1 2024, ending March 31, 2024. The company reported a net loss of £6.8 million, an improvement from £7.9 million in Q1 2023. Cash and cash equivalents stood at £12.9 million, down from £17.2 million at the end of 2023. Loss per share was £0.13, reduced from £0.15 in the comparable period.

Key developments include the full enrollment of a Phase 2 study involving 182 colorectal cancer patients and encouraging results from NUC-7738 combined with pembrolizumab in patients resistant to PD-1 inhibitors. NuCana's clinical programs, including NUC-3373 and NUC-7738, are on track for significant data readouts in 2024. The company expects its cash runway to extend into Q1 2025.

NuCana aims to announce multiple clinical data points in 2024, focusing on metastatic colorectal cancer and melanoma treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The company had previously been notified of non-compliance due to its closing bid price falling below $1.00 for 30 consecutive business days. However, after maintaining a minimum closing bid price of $1.00 or more for 10 consecutive business days, NuCana has now met the requirement, as confirmed by a Notification Letter from Nasdaq.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none

FAQ

What is the current stock price of NuCana plc American Depositary Share (NCNA)?

The current stock price of NuCana plc American Depositary Share (NCNA) is $1.205 as of December 24, 2024.

What is the market cap of NuCana plc American Depositary Share (NCNA)?

The market cap of NuCana plc American Depositary Share (NCNA) is approximately 4.7M.

What is NuCana plc's primary focus?

NuCana plc focuses on developing more effective and safer cancer treatments using its proprietary ProTide technology.

What is ProTide technology?

ProTide technology transforms widely used chemotherapy drugs into more potent and less toxic medications by overcoming cancer cell resistance mechanisms.

What are NuCana's key pipeline products?

NuCana's key pipeline products include NUC-3373, NUC-7738, and Acelarin, aimed at treating various solid tumors.

What recent financial results did NuCana announce?

NuCana reported £17.2 million in cash and cash equivalents as of December 31, 2023, with a net loss of £7.7 million for Q4 2023.

How did NuCana's ADS ratio change impact shareholders?

The ADS ratio change, effective as a one-for-twenty-five reverse split, aimed to enhance ADS liquidity and compliance with Nasdaq's minimum bid price requirement, without impacting shareholders' proportional equity interests.

What recent clinical data did NuCana present for NUC-3373?

NuCana presented data showing NUC-3373's favorable safety profile and encouraging efficacy in second-line colorectal cancer patients, including tumor volume reductions.

What is the significance of NUC-7738 in NuCana's pipeline?

NUC-7738 is significant as it is being evaluated for its potential to enhance the efficacy of anti-PD-1 therapies in patients with melanoma and other solid tumors.

Where is NuCana's primary operational region?

NuCana primarily operates in the United States.

What is the expected cash runway for NuCana?

NuCana expects its cash runway to extend into 2025, supporting the ongoing and planned clinical development programs.

What are the upcoming milestones for NuCana in 2024?

NuCana anticipates several important data updates across its ProTide pipeline, including results from the Phase 2 study of NUC-3373 and further evaluations of NUC-7738.

NuCana plc American Depositary Share

Nasdaq:NCNA

NCNA Rankings

NCNA Stock Data

4.73M
3.93M
0.53%
11.82%
2.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG